PMID- 23331131
OWN - NLM
STAT- MEDLINE
DCOM- 20130816
LR  - 20191210
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 40
IP  - 3
DP  - 2013 Mar
TI  - Nitric oxide signalling is involved in diarylheptanoid-induced increases in 
      femoral arterial blood flow in ovariectomized rats.
PG  - 240-9
LID - 10.1111/1440-1681.12058 [doi]
AB  - The mechanisms by which the hexane extract of Curcuma comosa increases femoral 
      blood flow (FBF) in ovariectomized rats are not known. Thus, the aim of the 
      present study was to investigate the acute effects and modes of action of the 
      diarylheptanoid (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (D3), a 
      phyto-oestrogen isolated from C. comosa, on FBF in ovariectomized rats. On Day 7 
      after ovariectomy, rats were injected once intra-arterially with D3 (100, 200, 
      400 and 800 mug/kg), 17beta-oestradiol (E2; 1, 2, 4 and 8 mug/kg) or vehicle. In some 
      experiments, rats were injected with N(G)-nitro-L-arginine methyl ester (L-NAME; 
      10 mg/kg) 120 min after 800 mug/kg D3 or 4 mug/kg E2. In other experiments, rats 
      were injected with 10 mg/kg L-NAME, 900 mug/kg 
      1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) or 900 mug/kg ICI 182 780 30 min 
      prior to the injection of 800 mug/kg D3 or 4 mug/kg E2. Mean arterial blood 
      pressure (mABP) and FBF were recorded using a pressure transducer and a laser 
      Doppler flow meter, respectively. Both D3 and E2 dose-dependently increased FBF 
      without changing mABP or heart rate. The EC(50) at 120 min for D3 and E2 was 
      195.8 and 1.8 mug/kg, respectively. In addition, D3 and E2 dose-dependently 
      decreased femoral vascular resistance (FVR). The EC(50) of D3 was about 100-fold 
      greater than that of E2. The effects of D3 and E2 on FBF and FVR were diminished 
      by intravenous injection of 10 mg/kg l-NAME. Furthermore, 30 min pretreatment 
      with L-NAME (10 mg/kg), ODQ (900 mug/kg) or ICI 182 780 (900 mug/kg) blocked the 
      effects of D3 and E2 on FBF and FVR. The results of the present study suggest 
      that the phyto-oestrogen D3 increases FBF in ovariectomized rats via oestrogen 
      receptor and nitric oxide-guanylyl cyclase signalling, which, in turn, relaxes 
      femoral vascular resistance.
CI  - (c) 2013 The Authors Clinical and Experimental Pharmacology and Physiology (c) 2013 
      Wiley Publishing Asia Pty Ltd.
FAU - Chaturapanich, Ganyapong
AU  - Chaturapanich G
AD  - Department of Physiology, Faculty of Science, Mahidol University,Bangkok, 
      Thailand.
FAU - Yamthed, Rungsima
AU  - Yamthed R
FAU - Piyachaturawat, Pawinee
AU  - Piyachaturawat P
FAU - Chairoungdua, Arthit
AU  - Chairoungdua A
FAU - Suvitayavat, Wisuda
AU  - Suvitayavat W
FAU - Kongsaktrakoon, Boontium
AU  - Kongsaktrakoon B
FAU - Suksamrarn, Apichart
AU  - Suksamrarn A
FAU - Pholpramool, Chumpol
AU  - Pholpramool C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (1,7-diphenyl-4,6-heptadien-3-ol)
RN  - 0 (Diarylheptanoids)
RN  - 0 (Phytoestrogens)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 8JQ5607IO5 (Heptanol)
RN  - EC 4.6.1.2 (Guanylate Cyclase)
SB  - IM
EIN - Clin Exp Pharmacol Physiol. 2013 Apr;40(4):306
MH  - Animals
MH  - Arterial Pressure/*drug effects/physiology
MH  - Curcuma/*chemistry
MH  - Diarylheptanoids
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Femoral Artery/*drug effects/metabolism/physiology
MH  - Guanylate Cyclase/biosynthesis
MH  - Heptanol/*analogs & derivatives/isolation & purification/pharmacology
MH  - Injections, Intra-Arterial
MH  - Molecular Structure
MH  - Nitric Oxide/*biosynthesis
MH  - Ovariectomy
MH  - Phytoestrogens/isolation & purification/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Regional Blood Flow/*drug effects
MH  - Signal Transduction
MH  - Vascular Resistance/drug effects
EDAT- 2013/01/22 06:00
MHDA- 2013/08/21 06:00
CRDT- 2013/01/22 06:00
PHST- 2012/03/02 00:00 [received]
PHST- 2013/01/14 00:00 [revised]
PHST- 2013/01/15 00:00 [accepted]
PHST- 2013/01/22 06:00 [entrez]
PHST- 2013/01/22 06:00 [pubmed]
PHST- 2013/08/21 06:00 [medline]
AID - 10.1111/1440-1681.12058 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2013 Mar;40(3):240-9. doi: 10.1111/1440-1681.12058.